Peter Fedichev on AI, Longevity & the Future of Anti-Aging Drugs MedTech World Middle East 2026

Why It Matters

The emergence of AI‑powered anti‑aging drugs could redefine pharma’s revenue landscape and accelerate investment in longevity, reshaping healthcare economics worldwide.

Key Takeaways

• AI platform decodes health data to identify anti‑aging targets.
• Aging drug could surpass JP1 agonist as pharma’s biggest revenue.
• Asia’s demographic shift fuels demand for longevity therapeutics.
• Regulatory competition will dictate where anti‑aging drugs are developed.
• Non‑incremental solutions essential; incremental approaches risk rapid obsolescence.

Summary

Peter Fedichev, speaking at MedTech World Middle East 2026, outlined how his company merges biotechnology with artificial intelligence to decode massive clinical and genetic datasets, aiming to uncover targets for drugs that address aging itself. He positioned anti‑aging therapeutics as the next trillion‑dollar asset class, potentially eclipsing the current JP1 agonist revenue stream that already generates near‑hundred‑billion‑dollar annual sales. The discussion highlighted three core insights: AI can reveal non‑incremental, high‑impact interventions; Asia’s rapidly aging populations create a pressing market for longevity drugs; and a global regulatory race will determine which region captures the lion’s share of future value. Fedichev emphasized that 100% of people age, yet aging is not classified as a disease, presenting a massive, untapped commercial opportunity. He quoted, “People should change the way they think about aging and medicine,” and noted that regional regulators are already convening to facilitate longevity trials, turning conferences into networking hubs that could assemble the critical mass of thinkers needed to launch anti‑aging drugs. The narrative underscored the urgency of embracing disruptive, AI‑driven solutions rather than incremental disease‑by‑disease approaches. If investors, pharma giants, and policymakers act on these signals, the next decade could see a paradigm shift from chronic‑disease treatment to proactive longevity therapeutics, reshaping revenue models, R&D pipelines, and global health outcomes.

Original Description

During MedTech World Middle East | Dubai 2026, Peter Fedichev, Co-founder and CEO of GERO, discusses how artificial intelligence and biotechnology are coming together to unlock new possibilities in longevity science.

GERO is using AI to analyse massive volumes of clinical and genetic data to identify new therapeutic targets. According to Fedichev, the next major breakthrough in biotechnology could be drugs that address aging itself, rather than treating diseases one by one.

He also highlights how demographic shifts, particularly in parts of Asia such as Japan, China, and Singapore, are increasing the urgency to develop therapies that support healthier aging populations.

Fedichev explains why regions that support research, data access, and regulatory progress in longevity science could play a major role in the future of drug development. Events like MedTech World provide a valuable platform to connect innovators, investors, and policymakers working toward the next generation of healthcare solutions.

#MedTechWorld #MTWMiddleEast2026 #Longevity #Biotech #AIinHealthcare #DrugDiscovery